Latest Articles
About This Stock
More About This Stock
Read
Read
PlasmaTech Announces Reverse Stock Split, Launches New Corporate Website; CEL-SCI Announces Closing Of Public Offering
CRMD Announces FDA IND Filing For Neutrolin; ZFGN Completes Enrollment Of Phase 2a Trial Of Beloranib
Article By:
BioMedReports
Friday, September 26, 2014 6:58 AM EDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease.